What is the Fiscal Year for TransCode Therapeutics?

Headquarters

Newton, Massachusetts, United States

Industry

Healthcare, Biotechnology Research Services

Stock Symbol

RNAZ

Website

Description

TransCode's goal is delivering a cancer-free future for all cancer patients. Our core belief is that cancer can be overcome through the intelligent design and efficient delivery of targeted therapeutics. Our lead therapeutic candidate, TTX-MC138, targets microRNA-10b, or miRNA-10b, considered the master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and several others. TransCode believes it has overcome this barrier, opening the door to a broad array of cancer therapies -- a disease with the highest unmet need that affects everyone. It is through the design and optimization of this technology that TransCode has devised an elegant solution -- TTX -- a proprietary delivery platform for the transport of targeted therapeutics to cancer cells. With their world class team and know how, TransCode has a rapidly expanding platform of drug candidates designed to target a variety of tumor indications with the goal of long-term treatment survival. Important Notice: Recruitment Fraud Alert We are aware of recruitment scams in which fraudsters pose as representatives of TransCode Therapeutics to deceive job seekers. Please note the following to protect yourself: • We NEVER ask for payment or personal financial information during the recruitment process. • All legitimate communication from our team will come from an official @transcodetherapeutics.com email address • Our hiring process always includes formal interviews—either virtual or in-person. • If you receive a job offer claiming to be from us, please do NOT respond. Report it to info@transcodetherapeutics.com.